A phase 1 study to evaluate the safety and efficacy of BG1805, a potent anti-CLL1 CAR-T therapy, in relapsed or refractory acute myeloid leukemia pediatric patients
Latest Information Update: 09 Jun 2021
At a glance
- Drugs BG 1805 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 09 Jun 2021 New trial record
- 07 Jun 2021 Results published in Guangzhou Baiji Gene Technology Media Release.
- 03 Jun 2021 According to a Guangzhou Bio-Gene media release, the company will present interim data from this study at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.